Compare Gilead Sciences, Inc. (GILD) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Illinois Tool Works Inc. — how do they compare? Gilead Sciences, Inc. trades at $146.99 (market cap $182.09B), while Illinois Tool Works Inc. trades at $263.26 (market cap $74.38B). The key difference: Gilead Sciences, Inc. is far larger — about 2.4× Illinois Tool Works Inc.'s market cap, and Illinois Tool Works Inc. pays the higher dividend (2.63%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 111 Days and Illinois Tool Works Inc. for 67 Days on average.
| GILD | ITW | |
|---|---|---|
Market Cap | $182.09B | $74.38B |
Volume | 4,960,247 | 1,125,477 |
Sector | Health | Industrials |
52-Week High | $155.80 | $299.60 |
52-Week Low | $116.74 | $241.07 |
Typical Hold Time | 111 Days | 67 Days |
Enterprise Value | $205.15B | $83.23B |
Dividend Yield | 2.23% | 2.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.10, up 1.99% with bullish technical signals and strong analyst support. The stock shows mixed fundamentals with a P/E of 17.84 and robust gross margins of 79.59%, though recent net income margin turned negative at -10.64%. Recent quarterly earnings beat expectations, and the company announced significant HIV prevention partnerships expanding access to lenacapavir across Latin America.
Outlook remains positive with 65% analyst buy ratings and $151.14 consensus target, though investors face risks from negative profitability metrics and increased investing outflows. The stock's current position near pivot point resistance at $147 suggests potential for breakout if earnings momentum continues.
ITW trades at $264.71, down 0.91% on the day, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 19.39% net margins and 104.65% ROE, though valuation multiples appear elevated. Recent dividend increase to $1.72 reinforces its Dividend King status with 59 years of consecutive growth. Operating cash flow remains robust at $3.13B, supporting continued shareholder returns.
Outlook remains mixed with analyst consensus target of $280.14 offering 5.8% upside, but technical indicators signal near-term pressure. The company faces headwinds in automotive and foodservice segments while maintaining strong organic growth prospects. Debt levels have increased to 55.54% of assets, requiring monitoring amid rising interest rates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
